Zura Bio Limited (NASDAQ: ZURA) is a Healthcare company (Biotechnology) with a market capitalization of $100M. The Maz Rating grades it against the other companies in its sector.
Zura Bio Limited's current Maz Rating and its five factor grades are for members: log in to see them.
At $1.03, Zura Bio Limited trades at 0.7x book value, with an EV/EBITDA of 0.9. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -54.0%, return on invested capital of -56.6% and a free cash flow yield of -81.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 11.29. Over the past 52 weeks the share price ranged from $0.93 to $7.44, with a beta of -0.04.
Zura Bio Limited does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 1 Strong Buy, 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Zura Bio Limited (ZURA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 34.3% / 30% · Interest income / Revenue 175900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 34.3% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 175900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 34.3% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 175900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 97.0% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 175900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.4% / 33.33% · (Cash+Recv) / Total Assets 96.4% / 33.33% · Interest income / Revenue 175900000.0% / 5% | Fail |
No. As of September 2026, Zura Bio Limited (ZURA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Zura Bio Limited is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 175900000.0% of each dividend: Zura Bio Limited's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.